Results 41 to 50 of about 37,527 (263)

Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer [PDF]

, 2013
BACKGROUND: The detection of serum tumor marker becomes a common method for screening tumors. However, this method has not been widely used for routine gastric cancer screening.
Chao-Zhu He, Kun-He Zhang, Nong-Hua Lv, Qing Li, Xiao-Hua Liu, Yan Hong   +5 more
core   +1 more source

Preoperative CRP(−)/CEA(−)/CA19-9(−)/non-T4 in Stage III Colorectal Cancer Is Favorable Risk for Recurrence

Journal of the Anus, Rectum and Colon, 2022
Objectives: We evaluated the prognostic impact of a novel C-reactive protein (CRP) cut-off value (0.6 mg/dl) and carcinoembryonic antigen (CEA)/carbohydrate antigen 19-9 (CA19-9) in stage II/III colorectal cancer.
Mitsunori Ushigome, Hideaki Shimada, Tomoaki Kaneko, Yasuyuki Miura, Yasuo Nagashima, Takayuki Suzuki, Satoru Kagami, Akiharu Kurihara, Kimihiko Funahashi   +8 more
doaj   +1 more source

Capecitabine as second-line treatment for metastatic cholangiocarcinoma: A report of two cases [PDF]

, 2002
Background: The management of recurrent, metastatic cholangiocarcinoma still remains a problem since this tumor entity is classified as chemotherapy-resistant.
Heinemann, Volker, Schalhorn, A., Stemmler, Joachim   +2 more
core   +1 more source

Elevated Preoperative Serum CA19-9 Levels in Patients with Hepatocellular Carcinoma Is Associated with Poor Prognosis after Resection

The Scientific World Journal, 2013
Serum levels of the tumor marker CA19-9 have been reported to be elevated in patients with hepatocellular carcinoma (HCC), but its clinicopathologic significance is still unknown.
Yu-Ling Chen, Chien-Hung Chen, Rey-Heng Hu, Ming-Chih Ho, Yung-Ming Jeng   +4 more
doaj   +1 more source

CA19-9 Benefits Prognostication of Pancreatic Cancer: Is It Time to Add CA19-9 to Its Staging Criteria? [PDF]

Annals of Surgical Oncology
Xiang, Gao, Haejin, In
openaire   +3 more sources

The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. [PDF]

, 2017
Pancreatic cancer is one the most lethal malignancies. Only a small proportion of patients with this disease benefit from surgery. Chemotherapy provides only a transient benefit.
Michael Pimienta, Michael Pimienta, Mouad Edderkaoui, Ruoxiang Wang, Stephen Pandol   +4 more
core   +2 more sources

Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy [PDF]

, 2017
Introduction: Surgical resection is the only curative treatment for patients with resectable pancreatic cancer. Unfortunately, 80%–85% of patients present with locally advanced or metastatic unresectable pancreatic cancer at the time of diagnosis ...
Ge, Long, Ma, Jichun, Pan, Bei, Song, Fujian, Tian, Jinhui, Zeraatkar, Dena, Zhou, Jianguo   +6 more
core   +1 more source

Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer [PDF]

, 2007
Objective: To date, no standard regimen for salvage chemotherapy after gemcitabine (Gem) failure has been defined for patients with advanced pancreatic cancer (PC). Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in
Boeck, Stefan, Bruns, Christiane J., Golf, Alexander, Haas, Michael, Heinemann, Volker, Issels, Rolf-Dieter, Laessig, Dorit, Moosmann, Nicolas, Schulz, Christoph, Wilkowski, Ralf   +9 more
core   +1 more source

Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma

Scientific Reports, 2021
Inflammation promotes tumor progression, induces invasion and metastatic spread. This retrospective study explored CRP, CA19-9, and routine laboratory values as preoperative prognostic factors in pancreatic cancer patients.
Anna M. Nurmi, Harri K. Mustonen, Ulf-Håkan Stenman, Hanna E. Seppänen, Caj H. Haglund   +4 more
doaj   +1 more source

Intralobar Pulmonary Sequestration Showing Increased Serum CA19-9 [PDF]

Tuberculosis and Respiratory Diseases, 2012
Carbohydrate antigen 19-9 (CA19-9) is a specific tumor marker of the biliary, pancreatic and gastrointestinal tracts. CA19-9 is occasionally elevated in serum in patiens with benign pulmonary diseases such as bronchiectasis, idiopathic interstitial pneumonia or collagen disease-associated pulmonary fibrosis.
Ahn, Yong Hwan, Song, Mi Jin, Park, Sang Hyun   +2 more
openaire   +2 more sources